Arginine vasopressin and pathophysiology of COVID-19: An innovative perspective - 09/10/21
Abstract |
In Covid-19, systemic disturbances may progress due to development of cytokine storm and dysregulation of and plasma osmolarility due to high release of pro-inflammatory cytokines and neuro-hormonal disorders. Arginine vasopressin (AVP) which is involve in the regulation of body osmotic system, body water content, blood pressure and plasma volume, that are highly disturbed in Covid-19 and linked with poor clinical outcomes. Therefore, this present study aimed to find the potential association between AVP serum level and inflammatory disorders in Covid-19. It has been observed by different recent studies that physiological response due to fever, pain, hypovolemia, dehydration, and psychological stress is characterized by activation release of AVP to counter-balance high blood viscosity in Covid-19 patients. In addition, activated immune cells mainly T and B lymphocytes and released pro-inflammatory cytokines stimulate discharge of stored AVP from immune cells, which in a vicious cycle trigger release of pro-inflammatory cytokines. Vasopressin receptor antagonists have antiviral and anti-inflammatory effects that may inhibit AVP-induced hyponatremia and release of pro-inflammatory cytokines in Covid-19. In conclusion, release of AVP from hypothalamus is augmented in Covid-19 due to stress, high pro-inflammatory cytokines, high circulating AngII and inhibition of GABAergic neurons. In turn, high AVP level leads to induction of hyponatremia, inflammatory disorders, and development of complications in Covid-19 by activation of NF-κB and NLRP3 inflammasome with release of pro-inflammatory cytokines. Therefore, AVP antagonists might be novel potential therapeutic modality in treating Covid-19 through mitigation of AVP-mediated inflammatory disorders and hyponatremia.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Covid-19 is associated with dysregulation of plasma osmolarility due to release of cytokines and neuro-hormonal disorders. |
• | Arginine vasopressin (AVP) is increased due to fever and dehydration to counter high blood viscosity in Covid-19 patients. |
• | T and B lymphocytes as well as pro-inflammatory cytokines stimulate discharge of stored AVP from immune cells in Covid-19. |
• | High AVP levels lead to hyponatremia and inflammatory disorders by activation of NF-κB and NLRP3 inflammasome. |
• | Vasopressin receptor antagonists have antiviral and anti-inflammatory effects that may inhibit progression of Covid-19. |
Keywords : Covid-19, Arginine vasopressin, Hyponatremia
Plan
Vol 143
Article 112193- novembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.